Please login to the form below

Not currently logged in
Email:
Password:

dolutegravir

This page shows the latest dolutegravir news and features for those working in and with pharma, biotech and healthcare.

ViiV builds case for switching to its two-drug HIV combinations

ViiV builds case for switching to its two-drug HIV combinations

48-week data from the phase 3 TANGO study indicates that Dovato (dolutegravir/lamivudine) was just as effective as triple therapies that included Gilead’s tenofovir alafenamide fumarate (TAF) at suppressing ... diagnosed patients and Juluca

Latest news

  • ViiV bags EU okay for new two-drug HIV therapy ViiV bags EU okay for new two-drug HIV therapy

    Dovato – a fixed-dose combination of ViiV’s blockbuster integrase inhibitor Tivicay (dolutegravir) and the nucleoside reverse transcriptase inhibitor lamivudine – is integral to the company’s attempt to muscle out ... Dovato is the second

  • Shingrix lifts GSK in Q1, but two more vaccines are culled Shingrix lifts GSK in Q1, but two more vaccines are culled

    The bulk of GSK’s HIV sales come from its dolutegravir-based combination products Tivicay and Triumeq, but greater competition in the market from arch-rival Gilead Sciences with new products ... GSK is looking to a series of new two-drug HIV drugs to

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    Meanwhile, Dovato (dolutegravir/lamivudine) developed by GSK-led joint venture ViiV, is the first ever once-a-day two-drug STR for treatment-naïve patients.

  • Dovato approval key for Glaxo in HIV treatment Dovato approval key for Glaxo in HIV treatment

    Dovato (dolutegravir/lamivudine) is marketed by GSK-led joint venture ViiV, and is the first ever once-a-day two-drug STR for treating treatment-naïve patients. ... those who would otherwise be precluded from receiving [ViiV's] Triumeq

  • Advair generics and acquisitions to hit GSK in 2019 Advair generics and acquisitions to hit GSK in 2019

    Key milestones expected this year include FDA approval for its HIV combination dolutegravir lamivudine in the first half of the year, as well as the filing for its long-acting HIV

More from news
Approximately 6 fully matching, plus 49 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Developing your patient-centric strategy

    The 2013 PatientView survey likely scored ViiV well on the product front too, as 2013 saw the company’s HIV therapy Tivicay (dolutegravir) approved in the US and recommended for European

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics